Skip to main content

Year: 2025

MT Højgaard Holding A/S: MT Højgaard Holding sells Arssarnerit

MT Højgaard Holding has today entered into an agreement to sell its last business activity in Greenland, the technical contracting and service company Arssarnerit. The sale is expected to be completed in the second quarter of 2026, subject to the approval of the competition authorities. The buyer is VVS & El Firmaet A/S, which will take over all activities in Arssarnerit, including operating assets, inventory, ongoing projects, employees and guarantees for completed projects up to a certain limit. The price for the sold assets and liabilities corresponds to the book value. Prior to entering into the agreement, MT Højgaard Holding has divested the HVAC service business and all activities outside Nuuk to focus Arssarnerit on its original core business of technical contracting activities in the Nuuk area. This is the activity that VVS...

Continue reading

CHAR Technologies Announces Closing of Book on Fully Subscribed Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — CHAR Technologies Ltd. (“CHAR Tech” or the “Company”) (TSXV:YES), a leader in sustainable energy solutions, is pleased to announce that the Company has closed the order book on its previously announced non-brokered private placement (the “Offering”) of 5,000,000 units (each, a “Unit”) at a price of $0. 20 CAD per Unit for aggregate gross proceeds of$1 million CAD. The Offering has been fully subscribed with institutional investor representation. The closing is expected to occur by or around the end of the week of December 16th, or a later date that may be determined by the Company. The Offering is subject to certain closing conditions, including, but not limited to, the receipt of all necessary...

Continue reading

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU) In the STEP UP programme, people with obesity taking Wegovy® 7.2 mg lost an average of 20.7% body weight at 72 weeks; one in three people achieved 25% or more weight loss1* The higher dose adds a new option for substantial weight loss while preserving muscle function and maintaining the established cardiovascular health benefits of Wegovy®2Bagsværd, Denmark, 12 December 2025 – Today, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy® (semaglutide 7.2 mg), bringing it a step closer to offering individuals with obesity in the EU a new Wegovy® option for even greater weight loss. The new dose...

Continue reading

EdgeMode Announces Strategic Portfolio Review and Advancement of AI Data Center Development Pipeline in Spain

FORT LAUDERDALE, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) — EdgeMode, Inc. (OTC: EDGM) (“EdgeMode” or the “Company”) today announced the results of a recent internal review of certain legacy arrangements and provided an update on its expanding AI Data Center development portfolio in Spain. Internal Review of Legacy Agreements As part of a routine internal review, the Company identified issues within a Share exchange agreement completed earlier this year. The Company has issued notice of its intention to pursue rescission of that agreement based on information recently discovered. While the rescission process is subject to formal procedures and may require judicial action, the Company has taken the initial steps toward unwinding the transaction. The potential impact of this action represents less than 5.5% of the Company’s total AI...

Continue reading

LOBO Announces Integration of Experienced Solar Team into Jiangsu LOBO; Represents a Strong Entry into the PV Energy Storage Power Generation Sector

WUXI, China, Dec. 12, 2025 (GLOBE NEWSWIRE) — LOBO TECHNOLOGIES LTD. (NASDAQ: LOBO) (“LOBO” or the “Company”), a developer and manufacturer of electric mobility and smart energy solutions, today announced that its operating subsidiary, Jiangsu LOBO Electric Vehicle Co. Ltd. (“Jiangsu LOBO”), has onboarded the entire team of Shenzhen Xiangri Technology Co., Ltd. (“Shenzhen Xiangri”), including its research & development, sales and business operation teams. This integration establishes a new Solar Division within Jiangsu LOBO, decided to advance the Company’s entry into the photovoltaic (“PV”) energy-storage power generation market. Founded in 2012, the Shenzhen Xiangri team brings over twelve years of expertise in the solar PV industry, with a focus of manufacturing solar modules and delivering integrated system solutions....

Continue reading

DSV – CAPITAL MARKETS DAY 2026

We would like to invite institutional investors and analysts to attend our Capital Markets Day on 12 May 2026. A detailed programme will follow, but please mark this date in your calendar. The Capital Markets Day will be a hybrid event with live streaming. A recording of the Capital Markets Day will be made available on our investor website after the event. Please note that there are limited seats available for physical attendance. Date: Tuesday, 12 May 2026 Location: DSV, Hedehusene 630, 2640 Hedehusene, Denmark Sign-up for more information here: DSV Capital Markets Day 2026 – Sign up for more information ContactsInvestor Relations: Veronica Pontoppidan, IR Coordinator, tel. +45 41 11 06 46, veronica.pontoppidan@dsv.com Yours sincerely,DSV A/SAttachmentINVESTOR NEWS – DSV CAPITAL MARKETS DAY 2026

Continue reading

VCI Global Concludes ELOC to Simplify Capital Structure and Prepare for Multi-Subsidiary Listings

Enhance Capital Structure Supports Digital Asset Treasury Expansion and Institutional-Grade Growth Strategy KUALA LUMPUR, Malaysia, Dec. 12, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced the conclusion of its Equity Line of Credit (ELOC) facility. This strategic move streamlines the Company’s capital structure and positions the Company to concentrate on its highest-priority growth areas, including its Digital Asset Treasury (DaT) initiatives and its enterprise data and AI operations. VCI Global is well positioned to execute a disciplined, institutional-grade growth strategy across its technology and infrastructure businesses. Focused Growth on Digital Asset Treasury and Enterprise AI Operations VCI Global remains committed to advancing its enterprise data and AI...

Continue reading

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTSAn additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Sciences Virtual Investor ForumMelbourne, Australia, Dec. 12, 2025 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that an additional confirmed partial response (PR) has been recorded in the ongoing ACCENT trial in metastatic pancreatic cancer. The trial investigates the combination of the Company’s best-in-class FAK inhibitor narmafotinib in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane®). The additional PR brings the confirmed objective response rate (ORR) to 35% (19/55) which compares favourably to the ORR of 23% recorded for...

Continue reading

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. A final decision is anticipated from the European Commission in the first quarter of 2026. “We are pleased with CHMP’s positive recommendation based on the robust clinical evidence from SEQUOIA-HCM that demonstrated the safety and efficacy of MYQORZO in patients...

Continue reading

Rail Vision: Quantum AI Powers Next-Gen Rail Safety Breakthroughs

Rail Vision Enters the Quantum Transportation Market with Strategic Acquisition Agreement  Ra’anana, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, recently announced the signing of an agreement for a strategic transaction to acquire 51% ownership of Quantum Transportation Ltd. (the “Acquisition” and “Quantum Transportation”), a cutting-edge quantum computing and AI company specializing in error correction technologies. The closing of the Acquisition is expected to close in late December 2025 to early January 2026, subject to the satisfaction of customary closing conditions. Quantum Transportation holds an exclusive sublicense, for rail technologies...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.